Skip to main content
Norris Cotton Cancer Center
In This Section

Recently Opened Clinical Trials for August 2014

Alexey Danilov
Assistant Professor
Molecular Therapeutics
Piramal Life Sciences, Limited
A Phase I/Ib study of P1446A-05 in patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL)

Marc Ernstoff
Immunology and Cancer Immunotherapy
Acceleron Pharma Inc
A Phase 2 randomized, double-blind study of dalantercept plus axitinib compared to placebo plus axitnib in patients with advanced renal cell carcinoma

Merck and Company
Expanded access of MK-3475 in metastatic melanoma patients with limited to no treatment options

Lionel Lewis
Molecular Therapeutics
GlaxoSmithKline Group
BRF114144: A rollover study to provide continued treatment with GSK2118436 to subjects with BRAF mutation-positive tumors

GlaxoSmithKline Group
A two-part study to evaluate the effect of repeat oral dosing of GSK2118436 on cardiac repolarization in subjects with V600 BRAF mutation-positive tumors: An open-label, dose escalating safety leading study followed by a single-sequence, placebo-controlled, single-blind study

David Roberts
Cancer Imaging and Radiobiology
Quantification of ALA-induced PpIX fluorescence during brain tumor resection